GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
Stock · NYSE · Health Care
$49.51as of 10/16/2026
Price chart
Active signals
GSK Signal Track Record
How signals performed across all stocks →What GSK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +0.4% | 57% | October 6, 2026 |
| Bollinger Band Breakout | 28 | +2.3% | 64% | July 2, 2026 |
| 200-Day Moving Average TouchActive now | 26 | +3.3% | 73% | August 11, 2026 |
| Bollinger Band Breakdown | 21 | +0.6% | 52% | October 1, 2026 |
| Any 20-session window (baseline) | +0.9% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 66,841
- Website
- www.gsk.com/
Fundamentals
- 1-day range
- $48.98$49.84
- Market cap
- $105.65B
- P/E (trailing)
- 15.09
- P/E (forward)
- 9.96
- EPS (trailing)
- $1.18
- Dividend yield
- 3.92%
- Beta
- 1.21
- Avg. volume
- 4.21M
- Ex-dividend date
- August 14, 2026
- Dividend pay date
- October 8, 2026
Forecasts
9 analyst ratings
GSK plc American Depositary Shares (Each representing two Ordinary Shares) Competitors
Chosen by industry and closest market cap.
- GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)$49.51▲ 1.00%Market cap $105.65BP/E 15.09$1,592$2,282
- SNYSanofi ADS$40.61▲ 0.79%Market cap $104.60BP/E 21.77$69.75$91.15
- VRTXVertex Pharmaceuticals Incorporated Common Stock$499.74▼ 1.77%Market cap $122.68BP/E 29.32$403.16$560.25
- BMYBristol-Myers Squibb Company Common Stock$59.75▼ 1.35%Market cap $131.04BP/E 13.53$42.52$68.64
- REGNRegeneron Pharmaceuticals Inc. Common Stock$790.74▼ 0.70%Market cap $79.49BP/E 19.00$564$859.34
- PFEPfizer Inc. Common Stock$29.58▲ 0.48%Market cap $149.33BP/E 39.08$23.62$29.49
- TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)$19.67▲ 1.13%Market cap $53.78BP/E —$4,102$6,183
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GSK GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $105.65B | 15.09 | $49.51 | ▲ 1.00% | $1,592$2,282 |
| SNY Sanofi ADS | $104.60B | 21.77 | $40.61 | ▲ 0.79% | $69.75$91.15 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $122.68B | 29.32 | $499.74 | ▼ 1.77% | $403.16$560.25 |
| BMY Bristol-Myers Squibb Company Common Stock | $131.04B | 13.53 | $59.75 | ▼ 1.35% | $42.52$68.64 |
| REGN Regeneron Pharmaceuticals Inc. Common Stock | $79.49B | 19.00 | $790.74 | ▼ 0.70% | $564$859.34 |
| PFE Pfizer Inc. Common Stock | $149.33B | 39.08 | $29.58 | ▲ 0.48% | $23.62$29.49 |
| TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | $53.78B | — | $19.67 | ▲ 1.13% | $4,102$6,183 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Commonwealth Of Pennsylvania: Governor Shapiro Secures Over $800M Investment From GSK To Expand Operations, Creating Over 300 New Jobs; GSK Is Expanding Its Facilities In Upper Merion Township, With Construction Planned To Begin In 2027benzinga · 10/9/2026
- Commonwealth Of Pennsylvania: Governor Shapiro Secures Over $800M Investment From GSK To Expand Operations, Creating Over 300 New Jobs; GSK Is Expanding Its Facilities In Upper Merion Township, With Construction Planned To Begin In 2027Benzinga · 10/9/2026
- Viola Davis partners with GSK to educate adults 50 and older about their shingles riskYahoo · 10/8/2026
- Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend YieldsBenzinga · 10/8/2026
- GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research PartnershipsYahoo · 10/8/2026
- GSK (LSE:GSK) Stock May Trade Below Fair Value Despite Fresh Cabenuva Trial NewsYahoo · 10/7/2026
- GSK: The Gas Pedal Is Finally DownSeekingAlpha · 10/7/2026
- ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremiaYahoo · 10/6/2026
- Cerebras Systems’ Tough 2026 Continues: It’ll Double Soon According to One of The Biggest Global BanksYahoo · 10/5/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 378.40M
- Total value held
- $19.13B
- Institutional holders
- 1024
- Unknown67.66M
- Unknown58.66M
- Unknown34.52M
- Unknown25.20M
- Unknown11.80M
- Unknown11.72M
- Unknown11.03M
- Unknown10.29M
- Unknown9.04M
- Unknown7.51M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
GSK Plans $800M Pennsylvania Expansion Amid AI Drug Discovery Talks
GSK is expanding its Pennsylvania operations with an $800 million investment while exploring new AI drug discovery partnerships. Analysts note that strong HIV sales are expected to offset vaccine headwinds in the upcoming quarter. The company also filed for American Depositary Shares, potentially increasing its accessibility to US investors.
GSK Plans $800M Pennsylvania Expansion Amid AI Drug Discovery Talks. GSK is expanding its Pennsylvania operations with an $800 million investment while exploring new AI drug discovery partnerships. Analysts note that strong HIV sales are expected to offset vaccine headwinds in the upcoming quarter. The company also filed for American Depositary Shares, potentially increasing its accessibility to US investors.